BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protective protein naturally found in human gastric juice. In animal studies, it repairs intestinal lining damage, strengthens tight junctions between gut cells, reduces GI inflammation, and protects against NSAID-induced ulcers. A 2025 systematic review presented at the American College of Gastroenterology analyzed 36 studies and confirmed functional and structural improvements across multiple GI conditions. Human clinical data remains limited, but BPC-157 has a unique property among peptides: it is stable in gastric acid, which makes oral administration a viable route specifically for gut-related applications. This matters because most peptides break down in the stomach before they can reach intestinal tissue. For peptide basics, see our Peptide Therapy: Complete Guide to Benefits, Types, and Safety [2026].
Key Takeaways
- BPC-157 was originally isolated from human gastric juice and is naturally present in the GI tract
- Animal studies show it repairs tight junctions, reduces intestinal permeability, and protects against ulcers
- The 2025 ACG systematic review of 36 studies confirmed GI benefits across IBD, ulcer, and NSAID-injury models
- Oral BPC-157 is viable for gut applications because the peptide is stable in gastric acid
- Human clinical evidence is still in early stages; most data comes from preclinical (animal) research
What Is BPC-157 and Where Does It Come From?
BPC-157 is a 15-amino-acid peptide sequence derived from a larger protein called BPC (Body Protection Compound) that your body produces naturally in gastric juice. Researchers first isolated it from the protective mucus lining of the human stomach in the 1990s, and its name reflects what it appears to do at the cellular level: protect the body, with a particular affinity for the gastrointestinal tract.1
The synthetic version used in research is identical in amino acid sequence to the naturally occurring fragment. It is classified as a pentadecapeptide (15 amino acids). What makes BPC-157 unusual among peptides is its stability in gastric acid. Most peptides are degraded rapidly by stomach acid and digestive enzymes, but BPC-157 resists this breakdown. A 2025 commentary published in Inflammopharmacology described it as having the "radical property of being stable in gastric juice," which is the basis for oral dosing in gut-specific applications.2
BPC-157 is not FDA-approved for any medical use. All current evidence comes from preclinical studies and early-phase human research. This article summarizes that evidence for educational purposes. BPC-157 legality is covered in our FDA peptide ban article.
How Does BPC-157 Repair the Gut Lining?
The intestinal lining is a single-cell-thick barrier that separates the contents of your digestive tract from your bloodstream. When this barrier breaks down, a condition informally called "leaky gut" (increased intestinal permeability), partially digested food particles, bacteria, and toxins can cross into the bloodstream and trigger systemic inflammation.
BPC-157 appears to repair this barrier through several mechanisms documented in animal studies:
Tight junction protein upregulation. Tight junctions are the protein complexes that seal the gaps between intestinal epithelial cells. Research shows BPC-157 increases the expression of three key tight junction proteins: occludin, claudin, and ZO-1. It also restores their proper positioning along the cell membrane after damage, which directly reduces intestinal permeability.3
Cytoprotective effects. BPC-157 stimulates growth factor pathways including the growth hormone receptor (GHR) system and vascular endothelial growth factor (VEGF). These pathways accelerate tissue repair, increase blood flow to damaged areas, and support new cell growth in injured intestinal tissue.4
Anti-inflammatory action in the GI tract. In animal models of inflammatory bowel disease, BPC-157 reduces pro-inflammatory cytokines and modulates the NO (nitric oxide) system. This dual action addresses both the structural damage and the inflammatory cascade that perpetuates it.5
Gastric acid regulation. BPC-157 influences gastric acid secretion in a context-dependent way. In models with excessive acid production, it reduces secretion. In models with suppressed acid, it normalizes it. This adaptive regulation protects the stomach lining without swinging acid levels to an extreme in either direction.1
What Does the Animal Study Evidence Show for IBD and Ulcers?
The preclinical evidence for BPC-157 in gastrointestinal conditions spans over three decades and 36 published studies, according to the 2025 ACG systematic review by Vasireddi et al. What the animal data shows across specific conditions.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Inflammatory bowel disease (IBD). In rodent models of both Crohn's disease and ulcerative colitis, BPC-157 reduced mucosal inflammation, decreased intestinal permeability, and improved histological scores. The peptide modulated the inflammatory response without the immunosuppressive effects associated with conventional IBD drugs like corticosteroids and biologics.6
Gastric and duodenal ulcers. Multiple studies show BPC-157 accelerates ulcer healing in rats, performing comparably to standard proton pump inhibitors in some models. It promotes angiogenesis (new blood vessel formation) at the ulcer site, which improves oxygen and nutrient delivery to healing tissue. BPC-157 ranks top in our 7 Best Peptides for Healing Injuries: Tendons, Joints & Gut guide.
NSAID-induced GI damage. Regular NSAID use (ibuprofen, naproxen, aspirin) is a leading cause of gastric ulcers and intestinal erosions. In animal models, BPC-157 administered alongside NSAIDs prevented or reversed the mucosal damage these drugs cause. This has obvious clinical relevance given the millions of people who take NSAIDs daily for pain management.4
Anastomotic healing. After bowel surgery, the reconnected sections (anastomoses) are vulnerable to leaking. BPC-157 improved the strength and integrity of anastomotic healing in animal surgical models, reducing leak rates and accelerating tissue remodeling.6
What Does the 2025 ACG Systematic Review Say?
The most comprehensive analysis of BPC-157's GI evidence to date was presented at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, AZ. Vasireddi, Vasireddi, and Vasireddi conducted a systematic review of 36 studies published between 1993 and 2025.
Key findings from the review:
- Of the 36 included studies, 35 were preclinical (animal) studies
- BPC-157 improved functional and structural outcomes in IBD, GI ulcer, NSAID-induced injury, GI fistula, and anastomotic repair models
- The peptide enhanced growth hormone receptor expression and modulated pathways involved in cell growth and angiogenesis
- It reduced inflammatory cytokines across all tested models
- BPC-157 is metabolized in the liver with a half-life under 30 minutes and is cleared by the kidneys
- Preclinical safety studies showed no adverse effects across multiple organ systems
- No clinical (human) safety data was available at the time of publication
The review concluded that BPC-157 is "an emerging adjunct to gastrointestinal therapies" but emphasized the need for controlled human trials before clinical recommendations can be made.6
Does BPC-157 Help with IBS Specifically?
This is an area where expectations need calibrating. IBS (irritable bowel syndrome) is a functional disorder driven by gut-brain axis signaling, visceral hypersensitivity, altered motility, and microbiome disruption. It is mechanistically different from IBD, ulcers, and structural barrier damage.
There is currently no published research showing BPC-157 directly improves IBS symptoms like abdominal pain, bloating, altered stool patterns, or visceral sensitivity. The peptide's documented mechanisms target structural repair, inflammation reduction, and mucosal protection, which are more relevant to IBD and ulcerative conditions than to the neurological and functional components of IBS.7
That said, some IBS patients have concurrent intestinal permeability issues, and addressing those could theoretically improve a subset of symptoms. Some practitioners report anecdotal improvement in IBS patients who use BPC-157, but this has not been studied in controlled settings. If you have IBS, BPC-157 is not a first-line recommendation based on current evidence. Discuss your options with a gastroenterologist familiar with peptide therapy.
Should BPC-157 for Gut Health Be Taken Orally or by Injection?
This is one of the most practical questions about BPC-157, and the answer differs from most peptides. For gut-specific applications, oral administration has a reasonable scientific basis.
| Factor | Oral BPC-157 | Injectable BPC-157 |
|---|---|---|
| Gastric stability | Stable in stomach acid | N/A (bypasses stomach) |
| Direct gut contact | Yes, contacts GI lining directly | No, enters bloodstream first |
| Systemic effects | Lower systemic bioavailability | Higher systemic bioavailability |
| Best for gut repair | Strong rationale | Weaker rationale for gut-specific use |
| Best for systemic healing | Weaker rationale | Strong rationale (tendons, joints) |
| Ease of use | Simple capsule | Requires reconstitution and injection |
Because BPC-157 is stable in gastric juice, oral dosing allows the peptide to make direct contact with the stomach and intestinal epithelium. For conditions like gastric ulcers, NSAID-induced damage, and intestinal permeability, this topical exposure to the gut lining is a potential advantage over injectable routes, which deliver the peptide systemically and rely on blood circulation to bring it to the GI tract.2
For systemic applications like tendon repair, joint healing, or muscle recovery, injectable BPC-157 remains the preferred route because it provides higher bioavailability outside the GI tract. Some practitioners use both routes together, though this combination has not been studied in controlled trials.
What Are Typical BPC-157 Protocols for Gut Health?
BPC-157 protocols are not standardized because there are no FDA-approved dosing guidelines. The dosing information below reflects what practitioners and researchers have used in clinical and research settings. This is not a treatment recommendation.
In animal studies, effective doses ranged from 10 mcg/kg to 50 mcg/kg of body weight. Translated to a 180-pound (82 kg) adult, this corresponds to approximately 250 to 500 mcg per dose. Most protocols for gut health use oral BPC-157 at 250 to 500 mcg taken on an empty stomach, once or twice daily, for cycles of 4 to 8 weeks.8
Taking the peptide on an empty stomach is considered preferable because it allows direct contact with the gastric and intestinal lining before food buffers the environment. The short half-life (under 30 minutes) means the peptide acts quickly but does not accumulate in the body, which is consistent with the favorable safety profile seen in animal studies.6
If you are interested in BPC-157 for gut health, work with a provider who has experience with BPC-157 and can monitor your progress with appropriate testing.
What Are the Limitations of the Current Evidence?
The BPC-157 gut health story is genuinely promising, but several limitations need to be acknowledged.
The vast majority of evidence comes from animal studies. Rats and mice metabolize drugs differently than humans, absorb peptides differently, and have different gut physiology. Positive results in rodents do not guarantee the same results in people. The 2025 ACG review included 36 studies, but only one involved human subjects, and it was a small pilot with just two participants.
There are no published Phase III clinical trials for any GI application of BPC-157. Phase II trials for IBD are underway, representing the most advanced human clinical program for this peptide, but results have not yet been published.6
Long-term safety data in humans does not exist. Animal studies show a clean safety profile with no adverse effects across multiple organ systems, but animal safety data does not always predict human outcomes.
Purity and sourcing are a practical concern. BPC-157 is available from many suppliers, and quality varies. Contamination, incorrect peptide sequences, and under-dosing are documented problems in the peptide market. Using a provider that sources from certified compounding pharmacies reduces these risks.
Frequently Asked Questions
Is BPC-157 FDA-approved for gut health?
No. BPC-157 is not FDA-approved for any medical use. All current evidence comes from preclinical animal studies and early-phase human research. It is available through compounding pharmacies and peptide suppliers but is used on an investigational basis.
Can I take BPC-157 orally for gut problems?
Oral BPC-157 has a reasonable scientific basis for gut-specific applications because the peptide is stable in stomach acid and makes direct contact with the gastrointestinal lining. Most practitioners who recommend BPC-157 for gut health prefer the oral route over injection for this reason.
Does BPC-157 help with IBS?
There is no published research showing BPC-157 directly improves IBS symptoms. IBS is a functional disorder driven by gut-brain signaling and visceral sensitivity, which are different mechanisms than the structural repair BPC-157 targets. Some patients report anecdotal improvement, but controlled evidence is lacking.
How long does it take for BPC-157 to heal the gut?
In animal studies, measurable improvements in gut integrity and inflammation occurred within 1 to 2 weeks. Practitioners who use BPC-157 for gut health typically recommend 4 to 8 week cycles. Individual response varies and there are no standardized timelines from human trials.
Are there side effects of BPC-157?
Animal studies consistently show no adverse effects across multiple organ systems. Human safety data is extremely limited. The most commonly reported anecdotal side effects in people who use BPC-157 include mild nausea, headache, and dizziness, though these are infrequent.
Can BPC-157 replace my IBD medication?
No. BPC-157 has not been proven effective for IBD in humans and should not replace prescribed medications like biologics, immunomodulators, or corticosteroids. If you are interested in adding BPC-157 to your IBD management, discuss it with your gastroenterologist.
What is the difference between BPC-157 and probiotics for gut health?
Probiotics introduce beneficial bacteria to the gut microbiome. BPC-157 works on the structural and inflammatory level, repairing tight junctions and reducing mucosal inflammation. They target different aspects of gut health and are not interchangeable.
Where should I source BPC-157 for gut health?
Use a provider that sources from certified US compounding pharmacies with third-party purity testing. The peptide market has documented quality issues including contamination and under-dosing. Pharmaceutical-grade sourcing is the only way to know what you are actually getting.
Medical References
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMC5333585
- Sikiric P, et al. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract. Inflammopharmacology. 2025. Springer
- Brainflow. BPC-157 for Gut Health: How This Peptide Supports Your Gut from the Inside Out. brainflow.co
- Gwyer D, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals. 2025;18(2):281. PMC11859134
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 may recover brain-gut axis and gut-brain axis function. Pharmaceuticals. 2023;16(5):676. PMC10224484
- Vasireddi N, et al. Oral peptide BPC-157: an emerging adjunct to gastrointestinal therapies? A systematic review. Am J Gastroenterol. 2025;120(10S):S808. ACG 2025
- Gyawali P. Can BPC-157 heal your gut? A gut doctor's honest opinion. guthealthdubai.com
- Oath Research. BPC-157 peptide: can healing outpace injury in gut or tendon repair? 2026. oathresearch.com
This article is for educational purposes only and does not constitute medical advice. BPC-157 is not FDA-approved for any medical condition. Consult your healthcare provider before starting any peptide protocol.
Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10